Dual GLP-1R/GcgR agonist studied for weight loss and NASH. Phase II/III trials ongoing.

📖 Read the full Survodutide research overview →

Evidence Tier: Tier 2 — Clinical Trials · Peptidings Verdict: Reasonable Bet